ContraFect Corp. (CFRX) NASDAQ

$0.30 0 (0.86%)

Market Cap: $11.94M

As of 08/12/22 04:00 PM EDT. Market closed.

(CFRX)

ContraFect Corp. (CFRX) NASDAQ

$0.30 0 (0.86%)

Market Cap: $11.94M

As of 08/12/22 04:00 PM EDT. Market closed.

ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. The Company intends to address life threatening ... read more

ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. The Company intends to address life threatening infections using its therapeutic product candidates from its platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. The Comapny believes that the properties of its lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. It has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with its lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Roger Pomerantz
Full Time Employees
33
URL
Address
28 Wells Ave Ste 3, New York, Yonkers, 10701-7045.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Roger Pomerantz
Full Time Employees
33
Address
28 Wells Ave Ste 3, New York, Yonkers, 10701-7045.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$0.30
Previous Close
$0.30
Days Range
$0.29 - $0.32
52 week range
$0.28 - $4.54
Volume
2,694,855
Avg. Volume (30 days)
3,018,613
Market Cap
$11.94M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
39,332,721
Open
$0.30
Previous Close
$0.30
Days Range
$0.29 - $0.32
52 week range
$0.28 - $4.54
Volume
2,694,855
Avg. Volume (30 days)
3,018,613
Market Cap
$11.94M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
39,332,721

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR CONTRAFECT CORP
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Messinger Michael Chief Financial Officer Dec 13, 2019 Buy $0.37 5,000 1,850 19,091 Dec 16, 2019, 06:28 AM
Sucoff Cary Director Dec 13, 2019 Buy $0.39 50,000 19,500 62,000 Dec 16, 2019, 06:26 AM
Low David N. Director Dec 13, 2019 Buy $0.43 300,000 129,000 370,550 Dec 16, 2019, 06:21 AM
Fosun Industrial Co., Ltd 10% Owner Dec 04, 2018 Sale $2.04 600,000 1,224,000 7,900,000 Dec 06, 2018, 04:53 PM
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 10% Owner Dec 04, 2018 Sale $2.04 600,000 1,224,000 7,900,000 Dec 06, 2018, 04:51 PM
BLECH ISAAC Director Jul 25, 2017 Buy $1.24 16,000 19,840 16,000 Jul 27, 2017, 04:29 PM
Muntner Joshua B SVP Business Development Jul 25, 2017 Buy $1.24 2,000 2,480 2,000 Jul 26, 2017, 04:52 PM
Messinger Michael SVP Finance Jul 25, 2017 Buy $1.24 800 992 14,091 Jul 26, 2017, 04:52 PM
Cassino Cara M Chief Medical Officer Jul 25, 2017 Buy $1.24 8,000 9,920 8,000 Jul 26, 2017, 04:51 PM
Bogdanos Natalie General Counsel Jul 25, 2017 Buy $1.24 800 992 800 Jul 26, 2017, 04:50 PM
Sucoff Cary Director Jul 25, 2017 Buy $1.24 12,000 14,880 12,000 Jul 26, 2017, 04:50 PM
Ricciardi Lisa Director Jul 25, 2017 Buy $1.24 9,600 11,904 9,600 Jul 26, 2017, 04:49 PM
Pomerantz Roger Director Jul 25, 2017 Buy $1.24 800 992 800 Jul 26, 2017, 04:48 PM
OTTO MICHAEL J. Director Jul 25, 2017 Buy $1.24 8,000 9,920 8,000 Jul 26, 2017, 04:47 PM
Low David N. Director Jul 25, 2017 Buy $1.24 40,000 49,600 70,550 Jul 26, 2017, 04:45 PM
BARER SOL J Director Jul 25, 2017 Buy $1.24 40,000 49,600 815,933 Jul 26, 2017, 04:44 PM
GILMAN STEVEN C CEO Jul 25, 2017 Buy $1.24 800 992 20,800 Jul 26, 2017, 04:42 PM
GILMAN STEVEN C CEO Jul 27, 2016 Buy $2.48 20,000 49,600 20,000 Jul 27, 2016, 05:18 PM
Couto Daniel SVP Manufacturing & Facilities Nov 17, 2015 Sale $3.81 2,872 10,937 0 Nov 18, 2015, 09:34 PM
Couto Daniel SVP Manufacturing & Facilities Nov 03, 2015 Sale $4.23 2,867 12,135 2,872 Nov 04, 2015, 04:38 PM
Couto Daniel SVP Manufacturing & Facilities Oct 20, 2015 Sale $4.48 2,867 12,854 5,739 Oct 22, 2015, 05:52 PM
Couto Daniel SVP Manufacturing & Facilities Oct 06, 2015 Sale $4.11 2,867 11,782 8,606 Oct 08, 2015, 04:43 PM
Couto Daniel SVP Manufacturing & Facilities Sep 22, 2015 Sale $4.76 2,867 13,644 11,473 Sep 23, 2015, 05:58 PM
Couto Daniel SVP Manufacturing & Facilities Sep 22, 2015 Sale $4.76 2,867 13,644 10,773 Sep 22, 2015, 06:17 PM
Couto Daniel SVP Manufacturing & Facilities Sep 08, 2015 Sale $4.90 2,867 14,057 14,340 Sep 10, 2015, 04:35 PM
GREGORY JULIA P CEO Mar 02, 2015 Buy $4.61 11,778 54,297 50,283 Mar 03, 2015, 09:35 PM
Couto Daniel SVP Manufacturing & Facilities Sep 11, 2014 Option Exercise $4.00 17,207 68,828 17,207 Oct 08, 2014, 02:22 PM
GREGORY JULIA P CEO Sep 11, 2014 Option Exercise $4.00 29,946 119,784 38,505 Oct 08, 2014, 02:21 PM
Wittekind Michael G. Chief Scientific Officer Sep 11, 2014 Option Exercise $4.00 17,893 71,572 17,893 Oct 08, 2014, 02:20 PM
Messinger Michael VP Finance Sep 11, 2014 Option Exercise $4.00 13,291 53,164 13,291 Oct 08, 2014, 02:19 PM
Kappel Barry J. SVP Business Development Sep 11, 2014 Option Exercise $4.00 12,532 50,128 12,532 Oct 08, 2014, 02:18 PM
Huang David B. Chief Medical Officer Sep 11, 2014 Option Exercise $4.00 23,901 95,604 23,901 Oct 08, 2014, 02:16 PM
Dong Nancy VP Controller Sep 11, 2014 Option Exercise $4.00 6,287 25,148 15,161 Oct 08, 2014, 02:15 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Messinger Michael Chief Financial Officer 12/13/2019 1,850
Sucoff Cary Director 12/13/2019 19,500
Low David N. Director 12/13/2019 129,000
Fosun Industrial Co., Ltd 10% Owner 12/04/2018 1,224,000
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 10% Owner 12/04/2018 1,224,000
BLECH ISAAC Director 07/25/2017 19,840
Muntner Joshua B SVP Business Development 07/25/2017 2,480
Messinger Michael SVP Finance 07/25/2017 992
Cassino Cara M Chief Medical Officer 07/25/2017 9,920
Bogdanos Natalie General Counsel 07/25/2017 992
Sucoff Cary Director 07/25/2017 14,880
Ricciardi Lisa Director 07/25/2017 11,904
Pomerantz Roger Director 07/25/2017 992
OTTO MICHAEL J. Director 07/25/2017 9,920
Low David N. Director 07/25/2017 49,600
BARER SOL J Director 07/25/2017 49,600
GILMAN STEVEN C CEO 07/25/2017 992
GILMAN STEVEN C CEO 07/27/2016 49,600
Couto Daniel SVP Manufacturing & Facilities 11/17/2015 10,937
Couto Daniel SVP Manufacturing & Facilities 11/03/2015 12,135
Couto Daniel SVP Manufacturing & Facilities 10/20/2015 12,854
Couto Daniel SVP Manufacturing & Facilities 10/06/2015 11,782
Couto Daniel SVP Manufacturing & Facilities 09/22/2015 13,644
Couto Daniel SVP Manufacturing & Facilities 09/22/2015 13,644
Couto Daniel SVP Manufacturing & Facilities 09/08/2015 14,057
GREGORY JULIA P CEO 03/02/2015 54,297
Couto Daniel SVP Manufacturing & Facilities 09/11/2014 68,828
GREGORY JULIA P CEO 09/11/2014 119,784
Wittekind Michael G. Chief Scientific Officer 09/11/2014 71,572
Messinger Michael VP Finance 09/11/2014 53,164
Kappel Barry J. SVP Business Development 09/11/2014 50,128
Huang David B. Chief Medical Officer 09/11/2014 95,604
Dong Nancy VP Controller 09/11/2014 25,148
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2021
03/31/2021
26.97%
3Q
12/31/2021
12/31/2017
-33.85%
16Q

Period of Report: 12/31/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2021
26.97%
3Q
12/31/2017
-33.85%
16Q